Levobunolol
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
(S)-5-{[3-(tert-Butylamino)-2-hydroxypropyl]oxy}-3,4-dihydronaphthalen-1(2H)-one | |
| Clinical data | |
| Trade names | Betagan |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a686011 |
| Pregnancy category |
|
| Routes of administration | Topical (eye drops) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Biological half-life | 20 hours |
| Identifiers | |
| CAS Number |
47141-42-4 |
| ATC code | S01ED03 (WHO) |
| PubChem | CID 39468 |
| IUPHAR/BPS | 570 |
| DrugBank |
DB01210 |
| ChemSpider |
36089 |
| UNII |
G6317AOI7K |
| KEGG |
D08115 |
| ChEBI |
CHEBI:6438 |
| ChEMBL |
CHEMBL1201237 |
| Chemical data | |
| Formula | C17H25NO3 |
| Molar mass | 291.385 g/mol |
| |
| |
| | |
Levobunolol (AK-Beta, Liquifilm, Betegan) is a non-selective beta blocker. It is used topically to manage glaucoma.
References
- Ishibashi T, Yokoi N, Kinoshita S (2003). "Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface.". Cornea 22 (8): 709–15. doi:10.1097/00003226-200311000-00001. PMID 14576520.
- Ogasawara H, Yoshida A, Fujio N, Konno S, Ishiko S (1999). "[Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers]". Nippon Ganka Gakkai Zasshi 103 (7): 544–50. PMID 10443129.
- Leung M, Grunwald J (1997). "Short-term effects of topical levobunolol on the human retinal circulation.". Eye 11 (3): 371–6. doi:10.1038/eye.1997.78. PMID 9373479.
| ||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
